Blood Testing Market Trends: Remote Testing and Software Adoption Gain Attention
The global blood testing market is witnessing substantial expansion as healthcare providers place greater emphasis on preventive screening, early disease detection, and routine patient monitoring. Advances in laboratory automation, artificial intelligence (AI), and remote diagnostic services are also reshaping the industry. According to Straits Research, the global blood testing market was valued at USD 100.7 billion in 2025 and is projected to reach USD 185.91 billion by 2034, registering a CAGR of 7.05% during 2026–2034.
Key Market Highlights:
- Market Size (2025): USD 100.7 Billion
- Market Size (2026): USD 107.80 Billion
- CAGR (2026–2034): 7.05%
- Forecast Year: 2034
- Projected Market Size (2034): USD 185.91 Billion
- Dominant Region: North America
- Fastest-Growing Region: Europe
Market Overview
Blood testing involves examining blood samples to identify diseases, evaluate organ function, and monitor treatment outcomes. Common applications include glucose testing, thyroid assessments, infectious disease screening, and routine health examinations. The growing need for reliable diagnostic information across hospitals, clinics, and independent laboratories continues to create demand for testing instruments, reagents, and digital laboratory solutions.
Market Drivers
The prevalence of chronic diseases remains a major demand factor. According to the IDF Diabetes Atlas 2025, approximately 589 million adults worldwide were living with diabetes in 2024. This patient population requires regular glucose and HbA1c assessments for disease management.
Preventive healthcare programmes and routine screening services also encourage blood testing adoption. Maternal healthcare, oncology monitoring, and diagnostic laboratory expansion across emerging economies provide additional demand avenues.
Market Challenges and Opportunities
High equipment costs, laboratory operating expenses, and differences in diagnostic infrastructure can restrict access to advanced blood testing services. Data security requirements and the need for reliable test interpretation also create operational challenges.
However, AI-assisted diagnostics, remote sample collection, and software-based laboratory management offer new revenue opportunities. Multiplex testing platforms and automated analysis systems provide additional avenues for manufacturers and diagnostic service providers.
Segment Analysis
By offerings, software is projected to record the fastest CAGR of 9.12%, reflecting demand for digital reporting and laboratory workflow management. By test type, thyroid stimulating hormone testing is expected to register an 8.08% CAGR.
Automated testing is projected to record an 8.35% CAGR, while remote testing is expected to be the fastest-growing end-use segment, with a CAGR of 10.24% through 2034.
Regional Analysis
North America dominated the market with a 38.5% share in 2025, reflecting its established diagnostic infrastructure and extensive laboratory testing network. The U.S. alone conducts more than 14 billion laboratory tests annually, according to the CDC.
Europe is projected to register the fastest CAGR of 8.74% during the forecast period. Established diagnostic industries in Germany and extensive NHS laboratory services in the U.K. contribute to regional demand. Asia Pacific accounted for 22.6% of the global market in 2025, with China, Japan, and India representing important diagnostic markets.
Competitive Landscape
The market features established diagnostic equipment manufacturers, laboratory service providers, and healthcare technology companies. Key players include:
- Abbott Diagnostics
- Bio-Rad Laboratories Inc.
- Roche Diagnostics
- Quest Diagnostics
Companies compete through automated testing platforms, diagnostic accuracy, expanded test portfolios, and digital laboratory capabilities.
Recent Developments
In May 2025, the U.S. FDA cleared Fujirebio's Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio test, which measures two blood-based proteins to aid in detecting amyloid plaques associated with Alzheimer's disease.
In June 2025, the FDA cleared Scopio Labs' X100/X100HT peripheral blood smear application with AI-based decision-support features for evaluating 23 red blood cell morphology parameters and detecting platelet clumps. These developments demonstrate the expanding role of advanced technologies in blood-based diagnostics.
Future Outlook
The blood testing market is positioned for continued expansion through 2034 as preventive screening, chronic disease monitoring, and digital diagnostic solutions become more integrated into healthcare delivery. Automation, AI-assisted interpretation, and remote testing are expected to create new opportunities for diagnostic laboratories, technology developers, and equipment manufacturers.
Click Here to Access the Comprehensive Report:https://straitsresearch.com/report/blood-testing-market
About Straits Research
Straits Research is a global market intelligence and consulting company that provides industry insights, market analysis, and strategic research solutions. The company delivers data-driven reports to help businesses understand industry developments, identify emerging opportunities, and make informed decisions across diverse sectors.
